OrganOx metra® System Approved for Liver Transplantation in Canada

More articles

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

OrganOx Ltd, a world-leading organ medical technology company, today announced Health Canada has approved the OrganOx metra® System for use during liver transplantation. The OrganOx metra® System is currently commercially available for liver transplantation in the U.S., the U.K., and the European Union. The company plans to commercially launch the system in Canada in 2025.

The OrganOx metra® System utilizes normothermic machine perfusion, or NMP, to circulate oxygenated blood, medications, and nutrients to donated organs at normal body temperature and near physiological conditions. This innovative technology extends organ preservation time, allows pre-transplant clinical assessment of organ viability and can dramatically improve operational logistics for both transplant teams and patients.1

“We are thrilled to receive this authorization in Canada, further advancing our vision to improve clinical outcomes for liver transplant patients around the globe,” said Craig Marshall, CEO of OrganOx. “In the coming months we look forward to introducing the metra® to transplant centers across Canada.”

The performance of the metra® system has been evaluated across several clinical trials including the Consortium for Organ Preservation in Europe (COPE) European Trial, the first randomized trial to assess machine perfusion versus static cold storage in liver transplantation. Compared with static cold storage, the OrganOx metra® achieved a 50% lower level of graft injury despite a 54% longer mean preservation time.2

- Advertisement -spot_img

Latest